Inhibiting β-Catenin by β-Carboline-Type MDM2 Inhibitor for Pancreatic Cancer Therapy
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Inhibiting β-Catenin by β-Carboline-Type MDM2 Inhibitor for Pancreatic Cancer Therapy
Authors
Keywords
-
Journal
Frontiers in Pharmacology
Volume 9, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2018-01-17
DOI
10.3389/fphar.2018.00005
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Revisiting the role of Wnt/β-catenin signaling in prostate cancer
- (2018) Jeffrey A. Schneider et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- Therapeutic Potential of Targeting Wnt/β-Catenin Pathway in Treatment of Colorectal Cancer: Rational and Progress
- (2017) Afsane Bahrami et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- Baicalein has protective effects on the 17β-estradiol-induced transformation of breast epithelial cells
- (2017) Yan Chen et al. Oncotarget
- Wnt/β-catenin signaling in melanoma: Preclinical rationale and novel therapeutic insights
- (2016) Gongda Xue et al. CANCER TREATMENT REVIEWS
- Mucins and Wnt/β-catenin signaling in gastrointestinal cancers: an unholy nexus
- (2016) Priya Pai et al. CARCINOGENESIS
- Synthesis, antimycobacterial screening and ligand-based molecular docking studies on novel pyrrole derivatives bearing pyrazoline, isoxazole and phenyl thiourea moieties
- (2016) Shrinivas D. Joshi et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- The role of the wnt/β-catenin signaling pathway in formation and maintenance of bone and teeth
- (2016) Peipei Duan et al. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
- RAS isoforms and mutations in cancer at a glance
- (2016) G. Aaron Hobbs et al. JOURNAL OF CELL SCIENCE
- Medicinal Chemistry Strategies to Disrupt the p53-MDM2/MDMX Interaction
- (2016) Agostinho Lemos et al. MEDICINAL RESEARCH REVIEWS
- Small-molecule binding of the axin RGS domain promotes β-catenin and Ras degradation
- (2016) Pu-Hyeon Cha et al. Nature Chemical Biology
- Disruption of the RP-MDM2-p53 pathway accelerates APC loss-induced colorectal tumorigenesis
- (2016) S Liu et al. ONCOGENE
- Prodigiosin inhibits Wnt/β-catenin signaling and exerts anticancer activity in breast cancer cells
- (2016) Zhongyuan Wang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- β-Catenin C-terminal signals suppress p53 and are essential for artery formation
- (2016) Dario F. Riascos-Bernal et al. Nature Communications
- Inulanolide A as a new dual inhibitor of NFAT1-MDM2 pathway for breast cancer therapy
- (2016) Jiang-Jiang Qin et al. Oncotarget
- Direct Targeting of β-Catenin by a Small Molecule Stimulates Proteasomal Degradation and Suppresses Oncogenic Wnt/β-Catenin Signaling
- (2016) So-Young Hwang et al. Cell Reports
- RYBP predicts survival of patients with non-small cell lung cancer and regulates tumor cell growth and the response to chemotherapy
- (2015) Sukesh Voruganti et al. CANCER LETTERS
- 9-Hydroxycanthin-6-one, a β-Carboline Alkaloid from Eurycoma longifolia, Is the First Wnt Signal Inhibitor through Activation of Glycogen Synthase Kinase 3β without Depending on Casein Kinase 1α
- (2015) Kensuke Ohishi et al. JOURNAL OF NATURAL PRODUCTS
- Inhibiting NFAT1 for breast cancer therapy: New insights into the mechanism of action of MDM2 inhibitor JapA
- (2015) Jiang-Jiang Qin et al. Oncotarget
- Identification of a new class of natural product MDM2 inhibitor: In vitro and in vivo anti-breast cancer activities and target validation
- (2015) Jiang-Jiang Qin et al. Oncotarget
- RYBP expression is associated with better survival of patients with hepatocellular carcinoma (HCC) and responsiveness to chemotherapy of HCC cells in vitro and in vivo
- (2015) Wei Wang et al. Oncotarget
- Mutant p53 in Cancer: New Functions and Therapeutic Opportunities
- (2014) Patricia A.J. Muller et al. CANCER CELL
- p53 as a target for the treatment of cancer
- (2014) Michael J. Duffy et al. CANCER TREATMENT REVIEWS
- Exploiting APC Function as a Novel Cancer Therapy
- (2014) Alyssa Lesko et al. CURRENT DRUG TARGETS
- Identification of a New Class of MDM2 Inhibitor That Inhibits Growth of Orthotopic Pancreatic Tumors in Mice
- (2014) Wei Wang et al. GASTROENTEROLOGY
- The CREB-Binding Protein Inhibitor ICG-001 Suppresses Pancreatic Cancer Growth
- (2014) M. D. Arensman et al. MOLECULAR CANCER THERAPEUTICS
- The pyrido[b]indole MDM2 inhibitor SP-141 exerts potent therapeutic effects in breast cancer models
- (2014) Wei Wang et al. Nature Communications
- Wnt/β-catenin signalling: from plasma membrane to nucleus
- (2013) Wantae Kim et al. BIOCHEMICAL JOURNAL
- Pharmacological modulation of beta-catenin and its applications in cancer therapy
- (2013) Ravi Thakur et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Emerging patterns of somatic mutations in cancer
- (2013) Ian R. Watson et al. NATURE REVIEWS GENETICS
- Molecularly targeted cancer therapy: some lessons from the past decade
- (2013) Min Huang et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Natural Product MDM2 Inhibitors: Anticancer Activity and Mechanisms of Action
- (2012) J.-J. Qin et al. CURRENT MEDICINAL CHEMISTRY
- Wnt/beta-Catenin Signaling and Small Molecule Inhibitors
- (2012) Andrey Voronkov et al. CURRENT PHARMACEUTICAL DESIGN
- The -Catenin Destruction Complex
- (2012) J. L. Stamos et al. Cold Spring Harbor Perspectives in Biology
- An intrinsically labile α-helix abutting the BCL9-binding site of β-catenin is required for its inhibition by carnosic acid
- (2012) Marc de la Roche et al. Nature Communications
- β-Catenin hits chromatin: regulation of Wnt target gene activation
- (2009) Christian Mosimann et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search